Global Sepsis and Septic Shock Market

Sepsis and Septic Shock Comprehensive Study by Type (Automated Diagnostics, Conventional Diagnostics), By End User (Hospitals, Pathology Center, Laboratories, Research Organization, Others), By Technology (Molecular Diagnostics, Flow Cytometry, Microfluidics, Biomarkers), By Pathogen (Bacterial Sepsis, Viral Sepsis, Fungal Sepsis, Others) Players and Region - Global Market Outlook to 2028

Sepsis and Septic Shock Market by XX Submarkets | Forecast Years 2023-2028 | CAGR: 8.2%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Sepsis and Septic Shock
Severe sepsis is defined as sepsis associated with organ dysfunction, hypotension or hyper fusion. Hypoperfusion abnormalities of end organs may include lactatemia, oliguria or an alteration in mental status. Septic shock is defined as sepsis associated with hypotension and perfusion abnormalities despite the provision of adequate fluid (volume) resuscitation. Perfusion abnormalities include lactic acidosis, oliguria or an acute alteration in mental status. Sepsis can cause bacterial infection, influenza, fungal infection, etc. Patients with septic shock who are receiving inotropic or vasopressor therapy might still exhibit perfusion abnormalities, despite the lack of hypotension. The factor affecting of sepsis and septic shock leads to cause death in hospitals worldwide due to this the market growth is increasing

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)
CAGR8.2%


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Sepsis and Septic Shock market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

AstraZeneca (United Kingdom), Eli Lilly and Company (United States), Roche (Switzerland), Pfizer (United States), Merck & Co. (United States), GlaxoSmithKline (United Kingdom), Novartis (Switzerland) and Johnson & Johnson (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Abbott Laboratories (United States), Medtronic (Ireland), Danaher Corporation (United States), Philips Healthcare (Netherland), 3M (United States) and GE Healthcare (United States).

Segmentation Overview
AMA Research has segmented the market of Global Sepsis and Septic Shock market by Type (Automated Diagnostics and Conventional Diagnostics) and Region.



On the basis of geography, the market of Sepsis and Septic Shock has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by By End User, the sub-segment i.e. Hospitals will boost the Sepsis and Septic Shock market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by By Technology, the sub-segment i.e. Molecular Diagnostics will boost the Sepsis and Septic Shock market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by By Pathogen, the sub-segment i.e. Bacterial Sepsis will boost the Sepsis and Septic Shock market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
The Growing Awareness of the Importance of Early Diagnosis and Treatment and Increasing Demand of Novel Sepsis Diagnostics and Treatment Approaches

Market Growth Drivers:
Rising Incidence of Hospital-Acquired Infections

Challenges:
Shortage of Skilled Healthcare Professional

Restraints:
High Cost of Automated Diagnostic Devices

Opportunities:
Development of Rapid Diagnostic Techniques for Early Sepsis Diagnosis

Market Leaders and their expansionary development strategies
On October 2023, Eli Lilly and Company and AbCellera Biologics Inc. announced a collaboration to develop novel antibody therapies for sepsis. The two companies will combine their expertise in antibody discovery and development to identify and advance antibody candidates that are target the underlying mechanisms of sepsis.
On October 2023, Personalis, Inc. announced the launch of its SepsiDx genomic test for the diagnosis of sepsis. The test is designed to identify patients with sepsis early in the course of the disease, when treatment is most effective. The SepsiDx test is a blood test that analyzes the activity of 1,253 genes to identify a signature that is associated with sepsis. The test can be performed on patients of all ages, including those who are critically ill. The successful launch will help Personalis to maintain its position as a leader in this competitive market.


Key Target Audience
Government Bodies, Research Organizations, End User and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Automated Diagnostics
  • Conventional Diagnostics
By By End User
  • Hospitals
  • Pathology Center
  • Laboratories
  • Research Organization
  • Others

By By Technology
  • Molecular Diagnostics
  • Flow Cytometry
  • Microfluidics
  • Biomarkers

By By Pathogen
  • Bacterial Sepsis
  • Viral Sepsis
  • Fungal Sepsis
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Incidence of Hospital-Acquired Infections
    • 3.3. Market Challenges
      • 3.3.1. Shortage of Skilled Healthcare Professional
    • 3.4. Market Trends
      • 3.4.1. The Growing Awareness of the Importance of Early Diagnosis and Treatment
      • 3.4.2. Increasing Demand of Novel Sepsis Diagnostics and Treatment Approaches
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Sepsis and Septic Shock, by Type, By End User, By Technology, By Pathogen and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Sepsis and Septic Shock (Value)
      • 5.2.1. Global Sepsis and Septic Shock by: Type (Value)
        • 5.2.1.1. Automated Diagnostics
        • 5.2.1.2. Conventional Diagnostics
      • 5.2.2. Global Sepsis and Septic Shock by: By End User (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Pathology Center
        • 5.2.2.3. Laboratories
        • 5.2.2.4. Research Organization
        • 5.2.2.5. Others
      • 5.2.3. Global Sepsis and Septic Shock by: By Technology (Value)
        • 5.2.3.1. Molecular Diagnostics
        • 5.2.3.2. Flow Cytometry
        • 5.2.3.3. Microfluidics
        • 5.2.3.4. Biomarkers
      • 5.2.4. Global Sepsis and Septic Shock by: By Pathogen (Value)
        • 5.2.4.1. Bacterial Sepsis
        • 5.2.4.2. Viral Sepsis
        • 5.2.4.3. Fungal Sepsis
        • 5.2.4.4. Others
      • 5.2.5. Global Sepsis and Septic Shock Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Sepsis and Septic Shock: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. AstraZeneca (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Eli Lilly and Company (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Roche (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pfizer (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Merck & Co. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. GlaxoSmithKline (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Novartis (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Johnson & Johnson (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Sepsis and Septic Shock Sale, by Type, By End User, By Technology, By Pathogen and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Sepsis and Septic Shock (Value)
      • 7.2.1. Global Sepsis and Septic Shock by: Type (Value)
        • 7.2.1.1. Automated Diagnostics
        • 7.2.1.2. Conventional Diagnostics
      • 7.2.2. Global Sepsis and Septic Shock by: By End User (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Pathology Center
        • 7.2.2.3. Laboratories
        • 7.2.2.4. Research Organization
        • 7.2.2.5. Others
      • 7.2.3. Global Sepsis and Septic Shock by: By Technology (Value)
        • 7.2.3.1. Molecular Diagnostics
        • 7.2.3.2. Flow Cytometry
        • 7.2.3.3. Microfluidics
        • 7.2.3.4. Biomarkers
      • 7.2.4. Global Sepsis and Septic Shock by: By Pathogen (Value)
        • 7.2.4.1. Bacterial Sepsis
        • 7.2.4.2. Viral Sepsis
        • 7.2.4.3. Fungal Sepsis
        • 7.2.4.4. Others
      • 7.2.5. Global Sepsis and Septic Shock Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Sepsis and Septic Shock: by Type(USD Million)
  • Table 2. Sepsis and Septic Shock Automated Diagnostics , by Region USD Million (2017-2022)
  • Table 3. Sepsis and Septic Shock Conventional Diagnostics , by Region USD Million (2017-2022)
  • Table 4. Sepsis and Septic Shock: by By End User(USD Million)
  • Table 5. Sepsis and Septic Shock Hospitals , by Region USD Million (2017-2022)
  • Table 6. Sepsis and Septic Shock Pathology Center , by Region USD Million (2017-2022)
  • Table 7. Sepsis and Septic Shock Laboratories , by Region USD Million (2017-2022)
  • Table 8. Sepsis and Septic Shock Research Organization , by Region USD Million (2017-2022)
  • Table 9. Sepsis and Septic Shock Others , by Region USD Million (2017-2022)
  • Table 10. Sepsis and Septic Shock: by By Technology(USD Million)
  • Table 11. Sepsis and Septic Shock Molecular Diagnostics , by Region USD Million (2017-2022)
  • Table 12. Sepsis and Septic Shock Flow Cytometry , by Region USD Million (2017-2022)
  • Table 13. Sepsis and Septic Shock Microfluidics , by Region USD Million (2017-2022)
  • Table 14. Sepsis and Septic Shock Biomarkers , by Region USD Million (2017-2022)
  • Table 15. Sepsis and Septic Shock: by By Pathogen(USD Million)
  • Table 16. Sepsis and Septic Shock Bacterial Sepsis , by Region USD Million (2017-2022)
  • Table 17. Sepsis and Septic Shock Viral Sepsis , by Region USD Million (2017-2022)
  • Table 18. Sepsis and Septic Shock Fungal Sepsis , by Region USD Million (2017-2022)
  • Table 19. Sepsis and Septic Shock Others , by Region USD Million (2017-2022)
  • Table 20. South America Sepsis and Septic Shock, by Country USD Million (2017-2022)
  • Table 21. South America Sepsis and Septic Shock, by Type USD Million (2017-2022)
  • Table 22. South America Sepsis and Septic Shock, by By End User USD Million (2017-2022)
  • Table 23. South America Sepsis and Septic Shock, by By Technology USD Million (2017-2022)
  • Table 24. South America Sepsis and Septic Shock, by By Pathogen USD Million (2017-2022)
  • Table 25. Brazil Sepsis and Septic Shock, by Type USD Million (2017-2022)
  • Table 26. Brazil Sepsis and Septic Shock, by By End User USD Million (2017-2022)
  • Table 27. Brazil Sepsis and Septic Shock, by By Technology USD Million (2017-2022)
  • Table 28. Brazil Sepsis and Septic Shock, by By Pathogen USD Million (2017-2022)
  • Table 29. Argentina Sepsis and Septic Shock, by Type USD Million (2017-2022)
  • Table 30. Argentina Sepsis and Septic Shock, by By End User USD Million (2017-2022)
  • Table 31. Argentina Sepsis and Septic Shock, by By Technology USD Million (2017-2022)
  • Table 32. Argentina Sepsis and Septic Shock, by By Pathogen USD Million (2017-2022)
  • Table 33. Rest of South America Sepsis and Septic Shock, by Type USD Million (2017-2022)
  • Table 34. Rest of South America Sepsis and Septic Shock, by By End User USD Million (2017-2022)
  • Table 35. Rest of South America Sepsis and Septic Shock, by By Technology USD Million (2017-2022)
  • Table 36. Rest of South America Sepsis and Septic Shock, by By Pathogen USD Million (2017-2022)
  • Table 37. Asia Pacific Sepsis and Septic Shock, by Country USD Million (2017-2022)
  • Table 38. Asia Pacific Sepsis and Septic Shock, by Type USD Million (2017-2022)
  • Table 39. Asia Pacific Sepsis and Septic Shock, by By End User USD Million (2017-2022)
  • Table 40. Asia Pacific Sepsis and Septic Shock, by By Technology USD Million (2017-2022)
  • Table 41. Asia Pacific Sepsis and Septic Shock, by By Pathogen USD Million (2017-2022)
  • Table 42. China Sepsis and Septic Shock, by Type USD Million (2017-2022)
  • Table 43. China Sepsis and Septic Shock, by By End User USD Million (2017-2022)
  • Table 44. China Sepsis and Septic Shock, by By Technology USD Million (2017-2022)
  • Table 45. China Sepsis and Septic Shock, by By Pathogen USD Million (2017-2022)
  • Table 46. Japan Sepsis and Septic Shock, by Type USD Million (2017-2022)
  • Table 47. Japan Sepsis and Septic Shock, by By End User USD Million (2017-2022)
  • Table 48. Japan Sepsis and Septic Shock, by By Technology USD Million (2017-2022)
  • Table 49. Japan Sepsis and Septic Shock, by By Pathogen USD Million (2017-2022)
  • Table 50. India Sepsis and Septic Shock, by Type USD Million (2017-2022)
  • Table 51. India Sepsis and Septic Shock, by By End User USD Million (2017-2022)
  • Table 52. India Sepsis and Septic Shock, by By Technology USD Million (2017-2022)
  • Table 53. India Sepsis and Septic Shock, by By Pathogen USD Million (2017-2022)
  • Table 54. South Korea Sepsis and Septic Shock, by Type USD Million (2017-2022)
  • Table 55. South Korea Sepsis and Septic Shock, by By End User USD Million (2017-2022)
  • Table 56. South Korea Sepsis and Septic Shock, by By Technology USD Million (2017-2022)
  • Table 57. South Korea Sepsis and Septic Shock, by By Pathogen USD Million (2017-2022)
  • Table 58. Taiwan Sepsis and Septic Shock, by Type USD Million (2017-2022)
  • Table 59. Taiwan Sepsis and Septic Shock, by By End User USD Million (2017-2022)
  • Table 60. Taiwan Sepsis and Septic Shock, by By Technology USD Million (2017-2022)
  • Table 61. Taiwan Sepsis and Septic Shock, by By Pathogen USD Million (2017-2022)
  • Table 62. Australia Sepsis and Septic Shock, by Type USD Million (2017-2022)
  • Table 63. Australia Sepsis and Septic Shock, by By End User USD Million (2017-2022)
  • Table 64. Australia Sepsis and Septic Shock, by By Technology USD Million (2017-2022)
  • Table 65. Australia Sepsis and Septic Shock, by By Pathogen USD Million (2017-2022)
  • Table 66. Rest of Asia-Pacific Sepsis and Septic Shock, by Type USD Million (2017-2022)
  • Table 67. Rest of Asia-Pacific Sepsis and Septic Shock, by By End User USD Million (2017-2022)
  • Table 68. Rest of Asia-Pacific Sepsis and Septic Shock, by By Technology USD Million (2017-2022)
  • Table 69. Rest of Asia-Pacific Sepsis and Septic Shock, by By Pathogen USD Million (2017-2022)
  • Table 70. Europe Sepsis and Septic Shock, by Country USD Million (2017-2022)
  • Table 71. Europe Sepsis and Septic Shock, by Type USD Million (2017-2022)
  • Table 72. Europe Sepsis and Septic Shock, by By End User USD Million (2017-2022)
  • Table 73. Europe Sepsis and Septic Shock, by By Technology USD Million (2017-2022)
  • Table 74. Europe Sepsis and Septic Shock, by By Pathogen USD Million (2017-2022)
  • Table 75. Germany Sepsis and Septic Shock, by Type USD Million (2017-2022)
  • Table 76. Germany Sepsis and Septic Shock, by By End User USD Million (2017-2022)
  • Table 77. Germany Sepsis and Septic Shock, by By Technology USD Million (2017-2022)
  • Table 78. Germany Sepsis and Septic Shock, by By Pathogen USD Million (2017-2022)
  • Table 79. France Sepsis and Septic Shock, by Type USD Million (2017-2022)
  • Table 80. France Sepsis and Septic Shock, by By End User USD Million (2017-2022)
  • Table 81. France Sepsis and Septic Shock, by By Technology USD Million (2017-2022)
  • Table 82. France Sepsis and Septic Shock, by By Pathogen USD Million (2017-2022)
  • Table 83. Italy Sepsis and Septic Shock, by Type USD Million (2017-2022)
  • Table 84. Italy Sepsis and Septic Shock, by By End User USD Million (2017-2022)
  • Table 85. Italy Sepsis and Septic Shock, by By Technology USD Million (2017-2022)
  • Table 86. Italy Sepsis and Septic Shock, by By Pathogen USD Million (2017-2022)
  • Table 87. United Kingdom Sepsis and Septic Shock, by Type USD Million (2017-2022)
  • Table 88. United Kingdom Sepsis and Septic Shock, by By End User USD Million (2017-2022)
  • Table 89. United Kingdom Sepsis and Septic Shock, by By Technology USD Million (2017-2022)
  • Table 90. United Kingdom Sepsis and Septic Shock, by By Pathogen USD Million (2017-2022)
  • Table 91. Netherlands Sepsis and Septic Shock, by Type USD Million (2017-2022)
  • Table 92. Netherlands Sepsis and Septic Shock, by By End User USD Million (2017-2022)
  • Table 93. Netherlands Sepsis and Septic Shock, by By Technology USD Million (2017-2022)
  • Table 94. Netherlands Sepsis and Septic Shock, by By Pathogen USD Million (2017-2022)
  • Table 95. Rest of Europe Sepsis and Septic Shock, by Type USD Million (2017-2022)
  • Table 96. Rest of Europe Sepsis and Septic Shock, by By End User USD Million (2017-2022)
  • Table 97. Rest of Europe Sepsis and Septic Shock, by By Technology USD Million (2017-2022)
  • Table 98. Rest of Europe Sepsis and Septic Shock, by By Pathogen USD Million (2017-2022)
  • Table 99. MEA Sepsis and Septic Shock, by Country USD Million (2017-2022)
  • Table 100. MEA Sepsis and Septic Shock, by Type USD Million (2017-2022)
  • Table 101. MEA Sepsis and Septic Shock, by By End User USD Million (2017-2022)
  • Table 102. MEA Sepsis and Septic Shock, by By Technology USD Million (2017-2022)
  • Table 103. MEA Sepsis and Septic Shock, by By Pathogen USD Million (2017-2022)
  • Table 104. Middle East Sepsis and Septic Shock, by Type USD Million (2017-2022)
  • Table 105. Middle East Sepsis and Septic Shock, by By End User USD Million (2017-2022)
  • Table 106. Middle East Sepsis and Septic Shock, by By Technology USD Million (2017-2022)
  • Table 107. Middle East Sepsis and Septic Shock, by By Pathogen USD Million (2017-2022)
  • Table 108. Africa Sepsis and Septic Shock, by Type USD Million (2017-2022)
  • Table 109. Africa Sepsis and Septic Shock, by By End User USD Million (2017-2022)
  • Table 110. Africa Sepsis and Septic Shock, by By Technology USD Million (2017-2022)
  • Table 111. Africa Sepsis and Septic Shock, by By Pathogen USD Million (2017-2022)
  • Table 112. North America Sepsis and Septic Shock, by Country USD Million (2017-2022)
  • Table 113. North America Sepsis and Septic Shock, by Type USD Million (2017-2022)
  • Table 114. North America Sepsis and Septic Shock, by By End User USD Million (2017-2022)
  • Table 115. North America Sepsis and Septic Shock, by By Technology USD Million (2017-2022)
  • Table 116. North America Sepsis and Septic Shock, by By Pathogen USD Million (2017-2022)
  • Table 117. United States Sepsis and Septic Shock, by Type USD Million (2017-2022)
  • Table 118. United States Sepsis and Septic Shock, by By End User USD Million (2017-2022)
  • Table 119. United States Sepsis and Septic Shock, by By Technology USD Million (2017-2022)
  • Table 120. United States Sepsis and Septic Shock, by By Pathogen USD Million (2017-2022)
  • Table 121. Canada Sepsis and Septic Shock, by Type USD Million (2017-2022)
  • Table 122. Canada Sepsis and Septic Shock, by By End User USD Million (2017-2022)
  • Table 123. Canada Sepsis and Septic Shock, by By Technology USD Million (2017-2022)
  • Table 124. Canada Sepsis and Septic Shock, by By Pathogen USD Million (2017-2022)
  • Table 125. Mexico Sepsis and Septic Shock, by Type USD Million (2017-2022)
  • Table 126. Mexico Sepsis and Septic Shock, by By End User USD Million (2017-2022)
  • Table 127. Mexico Sepsis and Septic Shock, by By Technology USD Million (2017-2022)
  • Table 128. Mexico Sepsis and Septic Shock, by By Pathogen USD Million (2017-2022)
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Sepsis and Septic Shock: by Type(USD Million)
  • Table 138. Sepsis and Septic Shock Automated Diagnostics , by Region USD Million (2023-2028)
  • Table 139. Sepsis and Septic Shock Conventional Diagnostics , by Region USD Million (2023-2028)
  • Table 140. Sepsis and Septic Shock: by By End User(USD Million)
  • Table 141. Sepsis and Septic Shock Hospitals , by Region USD Million (2023-2028)
  • Table 142. Sepsis and Septic Shock Pathology Center , by Region USD Million (2023-2028)
  • Table 143. Sepsis and Septic Shock Laboratories , by Region USD Million (2023-2028)
  • Table 144. Sepsis and Septic Shock Research Organization , by Region USD Million (2023-2028)
  • Table 145. Sepsis and Septic Shock Others , by Region USD Million (2023-2028)
  • Table 146. Sepsis and Septic Shock: by By Technology(USD Million)
  • Table 147. Sepsis and Septic Shock Molecular Diagnostics , by Region USD Million (2023-2028)
  • Table 148. Sepsis and Septic Shock Flow Cytometry , by Region USD Million (2023-2028)
  • Table 149. Sepsis and Septic Shock Microfluidics , by Region USD Million (2023-2028)
  • Table 150. Sepsis and Septic Shock Biomarkers , by Region USD Million (2023-2028)
  • Table 151. Sepsis and Septic Shock: by By Pathogen(USD Million)
  • Table 152. Sepsis and Septic Shock Bacterial Sepsis , by Region USD Million (2023-2028)
  • Table 153. Sepsis and Septic Shock Viral Sepsis , by Region USD Million (2023-2028)
  • Table 154. Sepsis and Septic Shock Fungal Sepsis , by Region USD Million (2023-2028)
  • Table 155. Sepsis and Septic Shock Others , by Region USD Million (2023-2028)
  • Table 156. South America Sepsis and Septic Shock, by Country USD Million (2023-2028)
  • Table 157. South America Sepsis and Septic Shock, by Type USD Million (2023-2028)
  • Table 158. South America Sepsis and Septic Shock, by By End User USD Million (2023-2028)
  • Table 159. South America Sepsis and Septic Shock, by By Technology USD Million (2023-2028)
  • Table 160. South America Sepsis and Septic Shock, by By Pathogen USD Million (2023-2028)
  • Table 161. Brazil Sepsis and Septic Shock, by Type USD Million (2023-2028)
  • Table 162. Brazil Sepsis and Septic Shock, by By End User USD Million (2023-2028)
  • Table 163. Brazil Sepsis and Septic Shock, by By Technology USD Million (2023-2028)
  • Table 164. Brazil Sepsis and Septic Shock, by By Pathogen USD Million (2023-2028)
  • Table 165. Argentina Sepsis and Septic Shock, by Type USD Million (2023-2028)
  • Table 166. Argentina Sepsis and Septic Shock, by By End User USD Million (2023-2028)
  • Table 167. Argentina Sepsis and Septic Shock, by By Technology USD Million (2023-2028)
  • Table 168. Argentina Sepsis and Septic Shock, by By Pathogen USD Million (2023-2028)
  • Table 169. Rest of South America Sepsis and Septic Shock, by Type USD Million (2023-2028)
  • Table 170. Rest of South America Sepsis and Septic Shock, by By End User USD Million (2023-2028)
  • Table 171. Rest of South America Sepsis and Septic Shock, by By Technology USD Million (2023-2028)
  • Table 172. Rest of South America Sepsis and Septic Shock, by By Pathogen USD Million (2023-2028)
  • Table 173. Asia Pacific Sepsis and Septic Shock, by Country USD Million (2023-2028)
  • Table 174. Asia Pacific Sepsis and Septic Shock, by Type USD Million (2023-2028)
  • Table 175. Asia Pacific Sepsis and Septic Shock, by By End User USD Million (2023-2028)
  • Table 176. Asia Pacific Sepsis and Septic Shock, by By Technology USD Million (2023-2028)
  • Table 177. Asia Pacific Sepsis and Septic Shock, by By Pathogen USD Million (2023-2028)
  • Table 178. China Sepsis and Septic Shock, by Type USD Million (2023-2028)
  • Table 179. China Sepsis and Septic Shock, by By End User USD Million (2023-2028)
  • Table 180. China Sepsis and Septic Shock, by By Technology USD Million (2023-2028)
  • Table 181. China Sepsis and Septic Shock, by By Pathogen USD Million (2023-2028)
  • Table 182. Japan Sepsis and Septic Shock, by Type USD Million (2023-2028)
  • Table 183. Japan Sepsis and Septic Shock, by By End User USD Million (2023-2028)
  • Table 184. Japan Sepsis and Septic Shock, by By Technology USD Million (2023-2028)
  • Table 185. Japan Sepsis and Septic Shock, by By Pathogen USD Million (2023-2028)
  • Table 186. India Sepsis and Septic Shock, by Type USD Million (2023-2028)
  • Table 187. India Sepsis and Septic Shock, by By End User USD Million (2023-2028)
  • Table 188. India Sepsis and Septic Shock, by By Technology USD Million (2023-2028)
  • Table 189. India Sepsis and Septic Shock, by By Pathogen USD Million (2023-2028)
  • Table 190. South Korea Sepsis and Septic Shock, by Type USD Million (2023-2028)
  • Table 191. South Korea Sepsis and Septic Shock, by By End User USD Million (2023-2028)
  • Table 192. South Korea Sepsis and Septic Shock, by By Technology USD Million (2023-2028)
  • Table 193. South Korea Sepsis and Septic Shock, by By Pathogen USD Million (2023-2028)
  • Table 194. Taiwan Sepsis and Septic Shock, by Type USD Million (2023-2028)
  • Table 195. Taiwan Sepsis and Septic Shock, by By End User USD Million (2023-2028)
  • Table 196. Taiwan Sepsis and Septic Shock, by By Technology USD Million (2023-2028)
  • Table 197. Taiwan Sepsis and Septic Shock, by By Pathogen USD Million (2023-2028)
  • Table 198. Australia Sepsis and Septic Shock, by Type USD Million (2023-2028)
  • Table 199. Australia Sepsis and Septic Shock, by By End User USD Million (2023-2028)
  • Table 200. Australia Sepsis and Septic Shock, by By Technology USD Million (2023-2028)
  • Table 201. Australia Sepsis and Septic Shock, by By Pathogen USD Million (2023-2028)
  • Table 202. Rest of Asia-Pacific Sepsis and Septic Shock, by Type USD Million (2023-2028)
  • Table 203. Rest of Asia-Pacific Sepsis and Septic Shock, by By End User USD Million (2023-2028)
  • Table 204. Rest of Asia-Pacific Sepsis and Septic Shock, by By Technology USD Million (2023-2028)
  • Table 205. Rest of Asia-Pacific Sepsis and Septic Shock, by By Pathogen USD Million (2023-2028)
  • Table 206. Europe Sepsis and Septic Shock, by Country USD Million (2023-2028)
  • Table 207. Europe Sepsis and Septic Shock, by Type USD Million (2023-2028)
  • Table 208. Europe Sepsis and Septic Shock, by By End User USD Million (2023-2028)
  • Table 209. Europe Sepsis and Septic Shock, by By Technology USD Million (2023-2028)
  • Table 210. Europe Sepsis and Septic Shock, by By Pathogen USD Million (2023-2028)
  • Table 211. Germany Sepsis and Septic Shock, by Type USD Million (2023-2028)
  • Table 212. Germany Sepsis and Septic Shock, by By End User USD Million (2023-2028)
  • Table 213. Germany Sepsis and Septic Shock, by By Technology USD Million (2023-2028)
  • Table 214. Germany Sepsis and Septic Shock, by By Pathogen USD Million (2023-2028)
  • Table 215. France Sepsis and Septic Shock, by Type USD Million (2023-2028)
  • Table 216. France Sepsis and Septic Shock, by By End User USD Million (2023-2028)
  • Table 217. France Sepsis and Septic Shock, by By Technology USD Million (2023-2028)
  • Table 218. France Sepsis and Septic Shock, by By Pathogen USD Million (2023-2028)
  • Table 219. Italy Sepsis and Septic Shock, by Type USD Million (2023-2028)
  • Table 220. Italy Sepsis and Septic Shock, by By End User USD Million (2023-2028)
  • Table 221. Italy Sepsis and Septic Shock, by By Technology USD Million (2023-2028)
  • Table 222. Italy Sepsis and Septic Shock, by By Pathogen USD Million (2023-2028)
  • Table 223. United Kingdom Sepsis and Septic Shock, by Type USD Million (2023-2028)
  • Table 224. United Kingdom Sepsis and Septic Shock, by By End User USD Million (2023-2028)
  • Table 225. United Kingdom Sepsis and Septic Shock, by By Technology USD Million (2023-2028)
  • Table 226. United Kingdom Sepsis and Septic Shock, by By Pathogen USD Million (2023-2028)
  • Table 227. Netherlands Sepsis and Septic Shock, by Type USD Million (2023-2028)
  • Table 228. Netherlands Sepsis and Septic Shock, by By End User USD Million (2023-2028)
  • Table 229. Netherlands Sepsis and Septic Shock, by By Technology USD Million (2023-2028)
  • Table 230. Netherlands Sepsis and Septic Shock, by By Pathogen USD Million (2023-2028)
  • Table 231. Rest of Europe Sepsis and Septic Shock, by Type USD Million (2023-2028)
  • Table 232. Rest of Europe Sepsis and Septic Shock, by By End User USD Million (2023-2028)
  • Table 233. Rest of Europe Sepsis and Septic Shock, by By Technology USD Million (2023-2028)
  • Table 234. Rest of Europe Sepsis and Septic Shock, by By Pathogen USD Million (2023-2028)
  • Table 235. MEA Sepsis and Septic Shock, by Country USD Million (2023-2028)
  • Table 236. MEA Sepsis and Septic Shock, by Type USD Million (2023-2028)
  • Table 237. MEA Sepsis and Septic Shock, by By End User USD Million (2023-2028)
  • Table 238. MEA Sepsis and Septic Shock, by By Technology USD Million (2023-2028)
  • Table 239. MEA Sepsis and Septic Shock, by By Pathogen USD Million (2023-2028)
  • Table 240. Middle East Sepsis and Septic Shock, by Type USD Million (2023-2028)
  • Table 241. Middle East Sepsis and Septic Shock, by By End User USD Million (2023-2028)
  • Table 242. Middle East Sepsis and Septic Shock, by By Technology USD Million (2023-2028)
  • Table 243. Middle East Sepsis and Septic Shock, by By Pathogen USD Million (2023-2028)
  • Table 244. Africa Sepsis and Septic Shock, by Type USD Million (2023-2028)
  • Table 245. Africa Sepsis and Septic Shock, by By End User USD Million (2023-2028)
  • Table 246. Africa Sepsis and Septic Shock, by By Technology USD Million (2023-2028)
  • Table 247. Africa Sepsis and Septic Shock, by By Pathogen USD Million (2023-2028)
  • Table 248. North America Sepsis and Septic Shock, by Country USD Million (2023-2028)
  • Table 249. North America Sepsis and Septic Shock, by Type USD Million (2023-2028)
  • Table 250. North America Sepsis and Septic Shock, by By End User USD Million (2023-2028)
  • Table 251. North America Sepsis and Septic Shock, by By Technology USD Million (2023-2028)
  • Table 252. North America Sepsis and Septic Shock, by By Pathogen USD Million (2023-2028)
  • Table 253. United States Sepsis and Septic Shock, by Type USD Million (2023-2028)
  • Table 254. United States Sepsis and Septic Shock, by By End User USD Million (2023-2028)
  • Table 255. United States Sepsis and Septic Shock, by By Technology USD Million (2023-2028)
  • Table 256. United States Sepsis and Septic Shock, by By Pathogen USD Million (2023-2028)
  • Table 257. Canada Sepsis and Septic Shock, by Type USD Million (2023-2028)
  • Table 258. Canada Sepsis and Septic Shock, by By End User USD Million (2023-2028)
  • Table 259. Canada Sepsis and Septic Shock, by By Technology USD Million (2023-2028)
  • Table 260. Canada Sepsis and Septic Shock, by By Pathogen USD Million (2023-2028)
  • Table 261. Mexico Sepsis and Septic Shock, by Type USD Million (2023-2028)
  • Table 262. Mexico Sepsis and Septic Shock, by By End User USD Million (2023-2028)
  • Table 263. Mexico Sepsis and Septic Shock, by By Technology USD Million (2023-2028)
  • Table 264. Mexico Sepsis and Septic Shock, by By Pathogen USD Million (2023-2028)
  • Table 265. Research Programs/Design for This Report
  • Table 266. Key Data Information from Secondary Sources
  • Table 267. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Sepsis and Septic Shock: by Type USD Million (2017-2022)
  • Figure 5. Global Sepsis and Septic Shock: by By End User USD Million (2017-2022)
  • Figure 6. Global Sepsis and Septic Shock: by By Technology USD Million (2017-2022)
  • Figure 7. Global Sepsis and Septic Shock: by By Pathogen USD Million (2017-2022)
  • Figure 8. South America Sepsis and Septic Shock Share (%), by Country
  • Figure 9. Asia Pacific Sepsis and Septic Shock Share (%), by Country
  • Figure 10. Europe Sepsis and Septic Shock Share (%), by Country
  • Figure 11. MEA Sepsis and Septic Shock Share (%), by Country
  • Figure 12. North America Sepsis and Septic Shock Share (%), by Country
  • Figure 13. Global Sepsis and Septic Shock share by Players 2022 (%)
  • Figure 14. Global Sepsis and Septic Shock share by Players (Top 3) 2022(%)
  • Figure 15. Global Sepsis and Septic Shock share by Players (Top 5) 2022(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 18. AstraZeneca (United Kingdom) Revenue: by Geography 2022
  • Figure 19. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 20. Eli Lilly and Company (United States) Revenue: by Geography 2022
  • Figure 21. Roche (Switzerland) Revenue, Net Income and Gross profit
  • Figure 22. Roche (Switzerland) Revenue: by Geography 2022
  • Figure 23. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 24. Pfizer (United States) Revenue: by Geography 2022
  • Figure 25. Merck & Co. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Merck & Co. (United States) Revenue: by Geography 2022
  • Figure 27. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 28. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2022
  • Figure 29. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 30. Novartis (Switzerland) Revenue: by Geography 2022
  • Figure 31. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 32. Johnson & Johnson (United States) Revenue: by Geography 2022
  • Figure 33. Global Sepsis and Septic Shock: by Type USD Million (2023-2028)
  • Figure 34. Global Sepsis and Septic Shock: by By End User USD Million (2023-2028)
  • Figure 35. Global Sepsis and Septic Shock: by By Technology USD Million (2023-2028)
  • Figure 36. Global Sepsis and Septic Shock: by By Pathogen USD Million (2023-2028)
  • Figure 37. South America Sepsis and Septic Shock Share (%), by Country
  • Figure 38. Asia Pacific Sepsis and Septic Shock Share (%), by Country
  • Figure 39. Europe Sepsis and Septic Shock Share (%), by Country
  • Figure 40. MEA Sepsis and Septic Shock Share (%), by Country
  • Figure 41. North America Sepsis and Septic Shock Share (%), by Country
List of companies from research coverage that are profiled in the study
  • AstraZeneca (United Kingdom)
  • Eli Lilly and Company (United States)
  • Roche (Switzerland)
  • Pfizer (United States)
  • Merck & Co. (United States)
  • GlaxoSmithKline (United Kingdom)
  • Novartis (Switzerland)
  • Johnson & Johnson (United States)
Additional players considered in the study are as follows:
Abbott Laboratories (United States) , Medtronic (Ireland) , Danaher Corporation (United States) , Philips Healthcare (Netherland) , 3M (United States) , GE Healthcare (United States)
Select User Access Type

Key Highlights of Report


Jan 2024 207 Pages 73 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Sepsis and Septic Shock Market Quantitative research analysis
Global Sepsis and Septic Shock Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as AstraZeneca (United Kingdom), Eli Lilly and Company (United States), Roche (Switzerland), Pfizer (United States), Merck & Co. (United States), GlaxoSmithKline (United Kingdom), Novartis (Switzerland) and Johnson & Johnson (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"The Growing Awareness of the Importance of Early Diagnosis and Treatment " is seen as one of major influencing trends for Sepsis and Septic Shock Market during projected period 2022-2028.
The Sepsis and Septic Shock market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.
Analysts at AMA estimates Sepsis and Septic Shock Market to reach USD68000.0 Million by 2028.

Know More About Global Sepsis and Septic Shock Market Report?

Have a Query? Click Here

Other Related Reports

Upper-limb Robotic Neurorehabilitation Comprehensive Study by Type (Exoskeletons, End-effector Devices, Robotic Arms, Electrical Stimulation Devices, VR Systems, Others), By End User (Hospitals & Cli...
$ 3800
TMJ Disorders Comprehensive Study by Type (Muscular, Structural, Acute), Treatment (-Nonsurgical Treatments, Mouth Guards, Physical Therapy, Trigger Point Injections, Others, -Surgery, Arthrocentesis...
$ 3800
Hallux Rigidus Comprehensive Study by Treatment (-Non-Surgical Treatment, Shoe Modification, Orthotic Devices, Medications, Injection Therapy, Physical Therapy, -Surgical Treatment, Bone Spur Removal...
$ 3800
Teledermatology Comprehensive Study by Application (Direct consultations, Specialist referral, Online patient triage, Virtual prescription renewals, Patient follow-up care), Type (Synchronous, Asynch...
$ 3800
Retinal Detachment- Comprehensive Study by Type (Rhegmatogenous, Tractional, Exudative), Treatment Type (Surgical Others, Laser Therapy, Cryopexy, Others), End User (Hospitals, Speciality centre, Cl...
$ 3800
Autism Disorder and Treatment- Comprehensive Study by Therapy (Antipsychotic Drugs, Selective Serotonin Reuptake Inhibitors (SSRI) /Antidepressants, Stimulants, Sleep Medications, Others), Type (Auti...
$ 3800